Theragenics/Bard
This article was originally published in The Gray Sheet
Executive Summary
Five-year, non-exclusive distribution agreement with C.R. Bard for Theragenics' TheraSeed palladium-103 radioactive isotope seeds for treatment of prostate and other solid localized cancers is announced Jan. 5. The agreement covers distribution in the U.S., Canada and Puerto Rico